The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer - Nature
Briefly

The study on breast cancer involved a collaboration between various prestigious institutions including Precision Breast Cancer Institute, University of Cambridge, and Cancer Research UK, demonstrating a collective effort in cancer research.
Researchers from different hospitals and trusts across the UK were part of the breast cancer study, showcasing a diverse range of affiliations and expertise in the field.
Read at Nature
[
]
[
|
]